Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer
These findings suggest that neoadjuvant chemoimmunotherapy regimens were associated with higher pathologic and radiographic response rates compared with immunotherapy alone in locoregionally advanced HNSCC. These results call for phase 3 trials comparing these neoadjuvant regimens head to head.
Authors
- Linda X. Yin (ORCID: https://orcid.org/0000-0001-8515-2051)
- Kathryn M. Van Abel (ORCID: https://orcid.org/0000-0003-0513-4203)
- David M. Routman (ORCID: https://orcid.org/0000-0002-2768-003X)
- Binav Baral
- Harry E. Fuentes Bayne
- Patrick W. McGarrah (ORCID: https://orcid.org/0000-0002-0664-9447)
- Scott C. Lester (ORCID: https://orcid.org/0000-0001-5264-9811)
- Daniel L. Price (ORCID: https://orcid.org/0000-0003-3398-0562)
- Hannah Baratz (ORCID: https://orcid.org/0000-0003-3981-1460)
- C. Hidalgo (ORCID: https://orcid.org/0009-0002-6646-6260)
- Jessica Wilson
- Katharine R. Price
Institutions
- Mayo Clinic (US)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1001/jamaoto.2026.0080
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00